{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06302348",
            "orgStudyIdInfo": {
                "id": "PTC923-PKU-401"
            },
            "organization": {
                "fullName": "PTC Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Sepiapterin in Participants With Phenylketonuria (PKU)",
            "officialTitle": "A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin",
            "acronym": "EPIPHENY",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-sepiapterin-in-participants-with-phenylketonuria-pku"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-04",
            "studyFirstSubmitQcDate": "2024-03-04",
            "studyFirstPostDateStruct": {
                "date": "2024-03-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "PTC Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.",
            "detailedDescription": "The study includes 2 parts: Part 1 and 2. Part 1 is a sepiapterin-responsiveness test, and Part 2 is an open-label treatment period."
        },
        "conditionsModule": {
            "conditions": [
                "Phenylketonuria"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 56,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sepiapterin",
                    "type": "EXPERIMENTAL",
                    "description": "Participants \u22651 month of age with average screening blood Phe \u2265360 micromoles (\u03bcmol)/liter (L) will receive age- and weight-adjusted doses of sepiapterin orally once daily for 4 weeks in Part 1. Participants \u22651 month of age with average screening blood Phe \\<360 \u03bcmol/L will receive an age- and weight-adjusted dose of sepiapterin on Day 1 of Part 1 after protein/Phe load. Participants \\<1 month of age at screening will receive a single oral dose of sepiapterin on Day 1 of Part 1. Participants who are responsive to sepiapterin in Part 1 will progress to Part 2 and will continue to receive sepiapterin orally once daily for up to 6 years.",
                    "interventionNames": [
                        "Drug: Sepiapterin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sepiapterin",
                    "description": "Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.",
                    "armGroupLabels": [
                        "Sepiapterin"
                    ],
                    "otherNames": [
                        "PTC923"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean Change From Baseline in Full-scale Intelligence Quotient (FSIQ) Weschler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV) Score",
                    "description": "Analysis for participants aged \u226530 months to \\<6 years.",
                    "timeFrame": "Baseline, Year 2"
                },
                {
                    "measure": "Mean Change From Baseline in FSIQ Weschler Intelligence Scale for Children - Fifth Edition (WISC-V) Score",
                    "description": "Analysis for participants aged \u22656 years to 16 years.",
                    "timeFrame": "Baseline, Year 2"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change From Baseline in Phenylketonuria-Quality of Life (PKU-QOL) Questionnaire Score",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Score",
                    "timeFrame": "Baseline up to 4 years"
                },
                {
                    "measure": "Mean Change From Baseline in FSIQ (WPPSI-IV) Score",
                    "description": "Analysis for participants aged \u226530 months to \\<6 years.",
                    "timeFrame": "Baseline, Year 4"
                },
                {
                    "measure": "Mean Change From Baseline in FSIQ (WISC-V) Score",
                    "description": "Analysis for participants aged \u22656 years to 16 years.",
                    "timeFrame": "Baseline, Year 4"
                },
                {
                    "measure": "Change From Baseline in Mean Blood Phe Levels",
                    "timeFrame": "Baseline up to 6 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Women of childbearing potential must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for up to 90 days after the last dose of the study drug.\n* Established diagnosis of PKU with hyperphenylalaninemia (HPA) evidenced by at least 1 blood Phe measurement \\>600 \u03bcmol/L as documented in the medical history.\n* For participants \u22651 month of age, a minimum of 1 documented blood Phe measurement \\<480 \u03bcmol/L within 1 month prior to Screening.\n* For participants \u22651 month of age, 2 screening blood Phe concentration values must be in the range \u2265120 to \u2264480 \u03bcmol/L.\n* Willing to continue prescribed diet during Screening and Part 1.\n* For participants \u226530 months to \\<12 years of age, baseline FSIQ score \u226580.\n\nKey Exclusion Criteria:\n\n* History of allergies or adverse reactions to synthetic tetrahydrobiopterin (BH4) or sepiapterin.\n* Serious neuropsychiatric illness (for example, major depression) not currently under medical control or other concurrent disease or condition that, in the opinion of the investigator or sponsor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.\n* Treatment with BH4 supplementation (sapropterin dihydrochloride, KUVAN) within 3 months prior to Screening.\n* Current participation in another investigational drug study or use of any investigational agent within 30 days prior to Screening.\n* Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive Guanosine-5'-triphosphate (GTP) cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin 4-alphacarbinolamine dehydratase genes.\n* Any clinically significant laboratory abnormality as determined by the investigator.\n* Any past medical history of an abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated (Bedside Schwartz Equation) glomerular filtration rate (GFR) \\<60 milliliters (mL)/minute (min)/1.73 square meter (m\\^2).\n* Major surgery within the prior 90 days of Screening.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "12 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Patient Advocacy",
                    "role": "CONTACT",
                    "phone": "1-866-562-4620",
                    "email": "medinfo@ptcbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "Indiana University",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Romie",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Melissa Lah",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010661",
                    "term": "Phenylketonurias"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020739",
                    "term": "Brain Diseases, Metabolic, Inborn"
                },
                {
                    "id": "D000001928",
                    "term": "Brain Diseases, Metabolic"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000000592",
                    "term": "Amino Acid Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13566",
                    "name": "Phenylketonurias",
                    "asFound": "Phenylketonuria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5205",
                    "name": "Brain Diseases, Metabolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22498",
                    "name": "Brain Diseases, Metabolic, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M3932",
                    "name": "Amino Acid Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4529",
                    "name": "Phenylketonuria",
                    "asFound": "Phenylketonuria",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3036",
                    "name": "Inborn Amino Acid Metabolism Disorder",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "T14",
                    "name": "Phenylalanine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}